Recursion Pharmaceuticals dropped for a third straight day on Wednesday, slashing 6.29 percent to close at $4.77 apiece after investors mimicked the recent selling of three company executives.

According to data compiled by S&P Global Market Intelligence, Recursion Pharmaceuticals (NASDAQ: RXRX) stock was shedding more than 17% of its value week-to-date as of Thursday night.

Experts say old movie tickets act like time capsules, capturing how your seat reflected both access and your place in society.

The tiff between Titan and Lenskart shows brand warfare is shifting from billboards to algorithms So, when Titan discovered that Lenskart had embedded its trademarks—Titan, Titan Eye+, and ...

The release of 'King,' starring Shah Rukh Khan and Suhana Khan, has been postponed to 2027 due to SRK's shoulder injury sustained during an action seq ...